作者: Emmanuel Omari-Siaw , Qilong Wang , Congyong Sun , Zengquan Gu , Yuan Zhu
DOI: 10.1016/J.IJPHARM.2016.08.042
关键词:
摘要: An optimized perillaldehyde-loaded liposomal nanoformulation (PAH-LNF) was successfully applied to improve the pharmacological effect of perillaldehyde (PAH) in poloxamer 407-induced hyperlipidemia. Oral administration PAH-LNF (240mg/kg per body weight) rats significantly enhanced solubility and relative bioavailability (270.7%) compared free PAH with about 2.7-, 1.5-, 1.3-, 1.3- 1.5-fold increase AUC, T1/2, MRT, Cmax Tmax, respectively. Tissue distribution study also revealed accumulation liver, lungs, spleen, kidney, brain heart order decreasing affinity. Moreover, a significant decrease serum total cholesterol (TC), triglyceride (TG) low-density lipoprotein (LDL-C) simultaneous high-density (HDL-C) level observed chemically-induced hyperlipidemic mice which further confirmed PAH's anti-hyperlipidemic properties. Additionally, increased activities superoxide dismutase (SOD) glutathione peroxidase (GSH-Px) concurrent malondialdehyde (MDA) affirm antioxidant hepatoprotective effects PAH. Thus, promises be useful drug delivery system for development